vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and STEM, INC. (STEM). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $47.1M, roughly 1.8× STEM, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs -15.6%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 36.1%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.
IOVA vs STEM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $47.1M |
| Net Profit | — | $-16.0M |
| Gross Margin | 67.4% | 48.9% |
| Operating Margin | -84.7% | -17.7% |
| Net Margin | — | -33.9% |
| Revenue YoY | 17.7% | -15.6% |
| Net Profit YoY | — | 68.8% |
| EPS (diluted) | — | $-4.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $47.1M | ||
| Q3 25 | $67.5M | $38.2M | ||
| Q2 25 | $60.0M | $38.4M | ||
| Q1 25 | $49.3M | $32.5M | ||
| Q4 24 | $73.7M | $55.8M | ||
| Q3 24 | $58.6M | $29.3M | ||
| Q2 24 | $31.1M | $34.0M | ||
| Q1 24 | $715.0K | $25.5M |
| Q4 25 | — | $-16.0M | ||
| Q3 25 | $-91.3M | $-23.8M | ||
| Q2 25 | $-111.7M | $202.5M | ||
| Q1 25 | $-116.2M | $-25.0M | ||
| Q4 24 | — | $-51.1M | ||
| Q3 24 | $-83.5M | $-148.3M | ||
| Q2 24 | $-97.1M | $-582.3M | ||
| Q1 24 | $-113.0M | $-72.3M |
| Q4 25 | 67.4% | 48.9% | ||
| Q3 25 | 43.0% | 35.5% | ||
| Q2 25 | 5.5% | 33.4% | ||
| Q1 25 | -0.8% | 32.4% | ||
| Q4 24 | 68.7% | -4.4% | ||
| Q3 24 | 46.2% | 21.2% | ||
| Q2 24 | -0.8% | 27.6% | ||
| Q1 24 | — | -95.0% |
| Q4 25 | -84.7% | -17.7% | ||
| Q3 25 | -140.7% | -33.6% | ||
| Q2 25 | -189.8% | -34.8% | ||
| Q1 25 | -245.8% | -65.0% | ||
| Q4 24 | -117.5% | -84.4% | ||
| Q3 24 | -152.1% | -493.2% | ||
| Q2 24 | -327.6% | -1705.5% | ||
| Q1 24 | -16464.6% | -267.0% |
| Q4 25 | — | -33.9% | ||
| Q3 25 | -135.3% | -62.2% | ||
| Q2 25 | -186.2% | 527.8% | ||
| Q1 25 | -235.5% | -76.9% | ||
| Q4 24 | — | -91.6% | ||
| Q3 24 | -142.7% | -506.3% | ||
| Q2 24 | -312.2% | -1712.6% | ||
| Q1 24 | -15800.8% | -283.9% |
| Q4 25 | — | $-4.40 | ||
| Q3 25 | — | $-2.84 | ||
| Q2 25 | $-0.33 | $-1.79 | ||
| Q1 25 | $-0.36 | $-0.15 | ||
| Q4 24 | $-0.24 | $-15.29 | ||
| Q3 24 | $-0.28 | $-18.24 | ||
| Q2 24 | $-0.34 | $-71.81 | ||
| Q1 24 | $-0.42 | $-0.46 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $48.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $-249.4M |
| Total Assets | $913.2M | $308.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $48.9M | ||
| Q3 25 | $300.8M | $43.1M | ||
| Q2 25 | $301.2M | $40.8M | ||
| Q1 25 | $359.7M | $58.6M | ||
| Q4 24 | $323.8M | $56.3M | ||
| Q3 24 | $397.5M | $75.4M | ||
| Q2 24 | $412.5M | $89.6M | ||
| Q1 24 | $356.2M | $112.8M |
| Q4 25 | $698.6M | $-249.4M | ||
| Q3 25 | $702.3M | $-235.7M | ||
| Q2 25 | $698.5M | $-214.1M | ||
| Q1 25 | $767.9M | $-417.5M | ||
| Q4 24 | $710.4M | $-398.4M | ||
| Q3 24 | $773.5M | $-344.1M | ||
| Q2 24 | $768.5M | $-203.2M | ||
| Q1 24 | $680.0M | $371.6M |
| Q4 25 | $913.2M | $308.9M | ||
| Q3 25 | $904.9M | $362.6M | ||
| Q2 25 | $907.4M | $379.2M | ||
| Q1 25 | $966.7M | $405.1M | ||
| Q4 24 | $910.4M | $437.4M | ||
| Q3 24 | $991.1M | $537.8M | ||
| Q2 24 | $964.3M | $691.5M | ||
| Q1 24 | $869.8M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $8.2M |
| Free Cash FlowOCF − Capex | $-61.9M | — |
| FCF MarginFCF / Revenue | -71.3% | — |
| Capex IntensityCapex / Revenue | 10.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $8.2M | ||
| Q3 25 | $-78.7M | $11.4M | ||
| Q2 25 | $-67.4M | $-21.3M | ||
| Q1 25 | $-103.7M | $8.5M | ||
| Q4 24 | $-73.3M | $-14.7M | ||
| Q3 24 | $-59.0M | $-9.4M | ||
| Q2 24 | $-98.4M | $-11.9M | ||
| Q1 24 | $-122.3M | $-621.0K |
| Q4 25 | $-61.9M | — | ||
| Q3 25 | $-89.5M | — | ||
| Q2 25 | $-74.9M | — | ||
| Q1 25 | $-109.9M | — | ||
| Q4 24 | $-77.5M | — | ||
| Q3 24 | $-61.3M | — | ||
| Q2 24 | $-98.9M | — | ||
| Q1 24 | $-126.5M | — |
| Q4 25 | -71.3% | — | ||
| Q3 25 | -132.7% | — | ||
| Q2 25 | -124.9% | — | ||
| Q1 25 | -222.8% | — | ||
| Q4 24 | -105.1% | — | ||
| Q3 24 | -104.6% | — | ||
| Q2 24 | -317.9% | — | ||
| Q1 24 | -17685.3% | — |
| Q4 25 | 10.7% | — | ||
| Q3 25 | 16.1% | — | ||
| Q2 25 | 12.4% | — | ||
| Q1 25 | 12.6% | — | ||
| Q4 24 | 5.7% | — | ||
| Q3 24 | 3.9% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 583.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.11× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
STEM
Segment breakdown not available.
